1. Oncology

      MEASURING BIOMARKERS AT EVERY STAGE OF TUMOR DEVELOPMENT
      The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.

      Simoa assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.

      ONCOLOGY ASSAYS

      Available for Scientific Research

      c-MET CA 19-9 CA-125 CCL-11/ Eotaxin Assay Kit CEA
      CXCL13 Cytokine 3-Plex A TNFα, IL-6, IL-10 G-CSF GM-CSF GM-CSF (mouse)
      HE4/ WFDC2 IL-17A IL-18 IL-2 IL-3
      IL-4 IL-6 IL-6 (mouse) IP-10 LIF
      MIP-1β NSE PD-L1 PIGF PSA
      TGFα TGFβ TNFβ TRAIL VEGF
      Go Top
      国产在线 五月天激情电影,久久五月丁香中文字幕,亚洲 自拍色综合图区,亚洲中文精品第1页 国产二区,神马影院我不卡影院